This study aims to expand the work done on the previous (subproject 220) protocol by administering 2-CdA to patients with documented chronic progressive multiple sclerosis with a subcutaneous injection given for five days each month for six months in a double-blind, placebo- controlled, crossover design. MRI will be followed at baseline, and at 6, 12, 18 and 25 months after initiation of therapy. Standardized neurological rating assessments will be applied.
Showing the most recent 10 out of 871 publications